Market By Type, Industry Verticals, And Geography | Forecast 2021-2028
The detailed analysis of the global non-alcoholic steatohepatitis (NASH) biomarker market by Triton displays that, based on revenue, the market is assessed to grow at a CAGR of 21.28% during the evaluated years 2021-2028. In 2020, the market acquired revenue worth $772.4 million, and is estimated to garner $3700.0 million by 2028.
NASH, a destructive form of non-alcoholic fatty liver disease (NAFLD), often progresses to more severe disorders, such as cirrhosis and hepatocellular carcinoma.
Report scope can be customized per your requirements. Request For Customization
Non-alcoholic fatty liver disease (NAFLD) is among the leading causes of liver damage. Its pathological spectrum ranges from simple steatosis to various degrees of inflammation and liver cell damage, resulting in the condition known as non-alcoholic steatohepatitis. There is a high prevalence of alcoholic fatty liver and liver cancer cases, owing to the growing number of alcoholics each year. Also, NAFLD is associated with several metabolic comorbidities, including obesity, type-2 diabetes, dyslipidemia, and metabolic syndrome. Â
The study aims to get an overview of the non-alcoholic steatohepatitis (NASH) biomarker market in terms of various factors. Within this report, the key insight and the market summary regarding the NASH biomarker market have been discussed in detail. Also, the Impact of COVID-19 on the market, Porter’s five forces analysis, market attractiveness matrix, vendor scorecard, and key insights have been studied.Â
Factors such as the high prevalence of NASH among people and increasing incidence rates of metabolic comorbidities are fueling the growth of the studied market. Additionally, opportunities offered by developing regions and a surge in awareness pertaining to non-alcoholic fatty liver disease are key factors that the reviewed market can leverage to reach its projected growth.
However, the side-effects of NASH therapeutics and the unavailability of specialized diagnostic tests for NAFLD are restraints limiting the global market’s future growth.
Major geographies covered in the non-alcoholic steatohepatitis (NASH) biomarker market are:
•          North America: Canada and United States
•          Europe: Russia, Spain, United Kingdom, Germany, France, Italy, and Rest of Europe
•          Asia-Pacific: Australia & New Zealand, Japan, India, ASEAN countries, South Korea, China, and Rest of Asia-Pacific
•          Latin America: Brazil, Mexico, and Rest of Latin America
•          Middle East and Africa: United Arab Emirates, Turkey, Saudi Arabia, South Africa, and Rest of Middle East & Africa
The segmentation analysis of the NASH biomarker market includes:
•          Market by Type:
          o         Apoptosis Biomarker
          o         Serum Biomarker
          o         Oxidative stress Biomarker
          o         Hepatic fibrosis Biomarker
          o         Other Types
•          Market by Industry Verticals:
          o         Academic Research Key
          o         Diagnostic Lab
          o         Pharma & CRO Industry
          o         Hospital
The distinguished companies profiled in the NASH biomarker market are Novo Nordisk, Bristol Myers Squibb Company, Viking Therapeutics, Gilead Sciences Inc, Novartis AG, Genfit SA, Allergan, Zydus Cadila, Madrigal Pharmaceuticals, Siemens Healthineers, AstraZeneca, Pfizer Inc, and Merck & Co.
Market By Type, Application, E ..
VIEW REPORT
Market By Device Type, Therape ..
VIEW REPORT
Market By Type, Application, T ..
VIEW REPORT
Market By Technology, Applicat ..
VIEW REPORT
Market By Application, Type, E ..
VIEW REPORT
Market by Therapeutics, Diagno ..
VIEW REPORT
Market by Type, Application, E ..
VIEW REPORT
1. GLOBAL NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET - SUMMARY
2. INDUSTRY OUTLOOK
2.1. KEY INSIGHTS
2.1.1. DEMAND FOR NASH BIOMARKERS
2.1.2. UNMET MEDICAL NEEDS
2.2. IMPACT OF COVID-19 ON NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET
2.3. PORTER’S FIVE FORCES ANALYSIS
2.3.1. THREAT OF NEW ENTRANTS
2.3.2. THREAT OF SUBSTITUTE PRODUCTS
2.3.3. BARGAINING POWER OF BUYERS
2.3.4. BARGAINING POWER OF SUPPLIERS
2.3.5. COMPETITIVE RIVALRY
2.4. MARKET ATTRACTIVENESS INDEX
2.5. VENDOR LANDSCAPE
2.6. KEY MARKET STRATEGIES
2.6.1. CONTRACTS & PARTNERSHIPS
2.6.2. BUSINESS EXPANSIONS & DIVESTITURES
2.6.3. ACQUISITIONS & MERGERS
2.6.4. NEW PRODUCT LAUNCHES
2.7. MARKET DRIVERS
2.7.1. RISING PREVALENCE OF NASH
2.7.2. INCREASING INCIDENCE RATE OF METABOLIC COMORBIDITIES
2.8. MARKET RESTRAINTS
2.8.1. SIDE-EFFECTS OF NASH THERAPEUTICS
2.8.2. UNAVAILABILITY OF SPECIALIZED DIAGNOSTIC TEST FOR NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD)
2.9. MARKET OPPORTUNITIES
2.9.1. GROWTH OPPORTUNITIES IN DEVELOPING REGIONS
2.9.2. RISE IN AWARENESS PERTAINING TO NON-ALCOHOLIC FATTY LIVER DISEASE
3. GLOBAL NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET - BY TYPE
3.1. SERUM BIOMARKER
3.2. HEPATIC FIBROSIS BIOMARKER
3.3. APOPTOSIS BIOMARKER
3.4. OXIDATIVE STRESS BIOMARKER
3.5. OTHER TYPES
4. GLOBAL NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET - BY INDUSTRY VERTICALS
4.1. PHARMA & CRO INDUSTRY
4.2. DIAGNOSTIC LAB
4.3. ACADEMIC RESEARCH KEY
4.4. HOSPITAL
5. GLOBAL NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET - REGIONAL OUTLOOK
5.1. NORTH AMERICA
5.1.1. MARKET BY TYPE
5.1.2. MARKET BY INDUSTRY VERTICALS
5.1.3. COUNTRY ANALYSIS
5.1.3.1. UNITED STATES
5.1.3.2. CANADA
5.2. EUROPE
5.2.1. MARKET BY TYPE
5.2.2. MARKET BY INDUSTRY VERTICALS
5.2.3. COUNTRY ANALYSIS
5.2.3.1. GERMANY
5.2.3.2. FRANCE
5.2.3.3. UNITED KINGDOM
5.2.3.4. ITALY
5.2.3.5. RUSSIA
5.2.3.6. SPAIN
5.2.3.7. REST OF EUROPE
5.3. ASIA-PACIFIC
5.3.1. MARKET BY TYPE
5.3.2. MARKET BY INDUSTRY VERTICALS
5.3.3. COUNTRY ANALYSIS
5.3.3.1. CHINA
5.3.3.2. JAPAN
5.3.3.3. AUSTRALIA & NEW ZEALAND
5.3.3.4. INDIA
5.3.3.5. SOUTH KOREA
5.3.3.6. ASEAN COUNTRIES
5.3.3.7. REST OF ASIA-PACIFIC
5.4. LATIN AMERICA
5.4.1. MARKET BY TYPE
5.4.2. MARKET BY INDUSTRY VERTICALS
5.4.3. COUNTRY ANALYSIS
5.4.3.2. BRAZIL
5.4.3.3. REST OF LATIN AMERICA
5.5. MIDDLE EAST AND AFRICA
5.5.1. MARKET BY TYPE
5.5.2. MARKET BY INDUSTRY VERTICALS
5.5.3. COUNTRY ANALYSIS
5.5.3.2. UNITED ARAB EMIRATES
5.5.3.3. TURKEY
5.5.3.4. SOUTH AFRICA
5.5.3.5. REST OF MIDDLE EAST & AFRICA
6. COMPETITIVE LANDSCAPE
6.1. ALLERGAN
6.2. ASTRAZENECA
6.3. BRISTOL MYERS SQUIBB COMPANY
6.4. GENFIT SA
6.5. GILEAD SCIENCES INC
6.6. MADRIGAL PHARMACEUTICALS
6.7. MERCK & CO
6.8. NOVARTIS AG
6.9. NOVO NORDISK
6.10. PFIZER INC
6.11. SIEMENS HEALTHINEERS
6.12. VIKING THERAPEUTICS
6.13. ZYDUS CADILA
7. RESEARCH METHODOLOGY & SCOPE
7.1. RESEARCH SCOPE & DELIVERABLES
7.1.1.  OBJECTIVES OF STUDY
7.1.2.  SCOPE OF STUDY
7.2. SOURCES OF DATA
7.2.1.  PRIMARY DATA SOURCES
7.2.2.  SECONDARY DATA SOURCES
7.3. RESEARCH METHODOLOGY
7.3.1.  EVALUATION OF PROPOSED MARKET
7.3.2.  IDENTIFICATION OF DATA SOURCES
7.3.3.  ASSESSMENT OF MARKET DETERMINANTS
7.3.4.  DATA COLLECTION
7.3.5.  DATA VALIDATION & ANALYSIS
TABLE 1:Â Â Â Â Â Â GLOBAL NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET, REGIONAL OUTLOOK, 2021-2028 (IN $ MILLION)
TABLE 2:Â Â Â Â Â Â VENDOR LANDSCAPE
TABLE 3:Â Â Â Â Â Â LIST OF CONTRACTS & PARTNERSHIPS
TABLE 4:Â Â Â Â Â Â LIST OF BUSINESS EXPANSIONS & DIVESTITURES
TABLE 5:Â Â Â Â Â Â LIST OF ACQUISITIONS & MERGERS
TABLE 6:Â Â Â Â Â Â LIST OF NEW PRODUCT LAUNCHES
TABLE 7:Â Â Â Â Â Â GLOBAL NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET, BY TYPE, 2021-2028 (IN $ MILLION)
TABLE 8:Â Â Â Â Â Â GLOBAL NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET, BY INDUSTRY VERTICALS, 2021-2028 (IN $ MILLION)
TABLE 9:Â Â Â Â Â Â GLOBAL NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET, REGIONAL OUTLOOK, 2021-2028 (IN $ MILLION)
TABLE 10:Â Â Â Â NORTH AMERICA NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET, COUNTRY OUTLOOK, 2021-2028 (IN $ MILLION)
TABLE 11:Â Â Â Â NORTH AMERICA NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET, BY TYPE, 2021-2028 (IN $ MILLION)
TABLE 12:Â Â Â Â NORTH AMERICA NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET, BY INDUSTRY VERTICALS, 2021-2028 (IN $ MILLION)
TABLE 13:Â Â Â Â EUROPE NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER, COUNTRY OUTLOOK, 2021-2028 (IN $ MILLION)
TABLE 14:Â Â Â Â EUROPE NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET, BY TYPE, 2021-2028 (IN $ MILLION)
TABLE 15:Â Â Â Â EUROPE NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET, BY INDUSTRY VERTICALS, 2021-2028 (IN $ MILLION)
TABLE 16:Â Â Â Â ASIA-PACIFIC NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET, COUNTRY OUTLOOK, 2021-2028 (IN $ MILLION)
TABLE 17:Â Â Â Â ASIA-PACIFIC NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET, BY TYPE, 2021-2028 (IN $ MILLION)
TABLE 18:Â Â Â Â ASIA-PACIFIC NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET, BY INDUSTRY VERTICALS, 2021-2028 (IN $ MILLION)
TABLE 19:Â Â Â Â LATIN AMERICA NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET, COUNTRY OUTLOOK, 2021-2028 (IN $ MILLION)
TABLE 20:Â Â Â Â LATIN AMERICA NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET, BY TYPE, 2021-2028 (IN $ MILLION)
TABLE 21:Â Â Â Â LATIN AMERICA NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET, BY INDUSTRY VERTICALS, 2021-2028 (IN $ MILLION)
TABLE 22:Â Â Â Â MIDDLE EAST AND AFRICA NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET, COUNTRY OUTLOOK, 2021-2028 (IN $ MILLION)
TABLE 23:Â Â Â Â MIDDLE EAST AND AFRICA NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET, BY TYPE, 2021-2028 (IN $ MILLION)
TABLE 24:Â Â Â Â MIDDLE EAST AND AFRICA NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET, BY INDUSTRY VERTICALS, 2021-2028 (IN $ MILLION)
FIGURE 1:Â Â Â Â GLOBAL NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET 2021-2028 (IN $ MILLION)
FIGURE 2:    PORTER’S FIVE FORCES ANALYSIS
FIGURE 3:Â Â Â Â GLOBAL NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET, BY TYPE, 2020 & 2028 (IN %)
FIGURE 4:Â Â Â Â GLOBAL NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET, BY SERUM BIOMARKER, 2021-2028 (IN $ MILLION)
FIGURE 5:Â Â Â Â GLOBAL NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET, BY HEPATIC FIBROSIS BIOMARKER, 2021-2028 (IN $ MILLION)
FIGURE 6:Â Â Â Â GLOBAL NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET, BY APOPTOSIS BIOMARKER, 2021-2028 (IN $ MILLION)
FIGURE 7:Â Â Â Â GLOBAL NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET, BY OXIDATIVE STRESS BIOMARKER, 2021-2028 (IN $ MILLION)
FIGURE 8:Â Â Â Â GLOBAL NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET, BY OTHER TYPES, 2021-2028 (IN $ MILLION)
FIGURE 9:Â Â Â Â GLOBAL NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET, BY INDUSTRY VERTICALS, 2020 & 2028 (IN %)
FIGURE 10:Â GLOBAL NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET, BY PHARMA & CRO INDUSTRY, 2021-2028 (IN $ MILLION)
FIGURE 11:Â GLOBAL NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET, BY DIAGNOSTIC LAB, 2021-2028 (IN $ MILLION)
FIGURE 12:Â GLOBAL NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET, BY ACADEMIC RESEARCH KEY, 2021-2028 (IN $ MILLION)
FIGURE 13:Â GLOBAL NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET, BY HOSPITAL, 2021-2028 (IN $ MILLION)
FIGURE 14:Â UNITED STATES NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET 2021-2028 (IN $ MILLION)
FIGURE 15:Â CANADA NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET 2021-2028 (IN $ MILLION)
FIGURE 16:Â GERMANY NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET 2021-2028 (IN $ MILLION)
FIGURE 17:Â FRANCE NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET 2021-2028 (IN $ MILLION)
FIGURE 18:Â UNITED KINGDOM NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET 2021-2028 (IN $ MILLION)
FIGURE 19:Â ITALY NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET 2021-2028 (IN $ MILLION)
FIGURE 20:Â RUSSIA NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET 2021-2028 (IN $ MILLION)
FIGURE 21:Â SPAIN NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET 2021-2028 (IN $ MILLION)
FIGURE 22:Â REST OF EUROPE NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET 2021-2028 (IN $ MILLION)
FIGURE 23:Â CHINA NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET 2021-2028 (IN $ MILLION)
FIGURE 24:Â JAPAN NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET 2021-2028 (IN $ MILLION)
FIGURE 25:Â AUSTRALIA & NEW ZEALAND NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET 2021-2028 (IN $ MILLION)
FIGURE 26:Â INDIA NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET 2021-2028 (IN $ MILLION)
FIGURE 27:Â SOUTH KOREA NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET 2021-2028 (IN $ MILLION)
FIGURE 28:Â ASEAN COUNTRIES NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET 2021-2028 (IN $ MILLION)
FIGURE 29:Â REST OF ASIA-PACIFIC NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET 2021-2028 (IN $ MILLION)
FIGURE 30:Â MEXICO NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET 2021-2028 (IN $ MILLION)
FIGURE 31:Â BRAZIL NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET 2021-2028 (IN $ MILLION)
FIGURE 32:Â REST OF LATIN AMERICA NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET 2021-2028 (IN $ MILLION)
FIGURE 33:Â SAUDI ARABIA NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET 2021-2028 (IN $ MILLION)
FIGURE 34:Â UNITED ARAB EMIRATES NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET 2021-2028 (IN $ MILLION)
FIGURE 35:Â TURKEY NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET 2021-2028 (IN $ MILLION)
FIGURE 36:Â SOUTH AFRICA NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET 2021-2028 (IN $ MILLION)
FIGURE 37:Â REST OF MIDDLE EAST & AFRICA NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET 2021-2028 (IN $ MILLION)